Epileptic Encephalopathy CRISPR Cell Models for Drug Discovery

Epileptic encephalopathies (EEs) are severe brain disorders characterized by refractory seizures and developmental regression. The global incidence of epilepsy is approximately 50 million people (WHO, 2023), with a significant proportion being EE cases. Onset typically occurs in infancy or early childhood. Mortality is elevated due to sudden unexpected death in epilepsy (SUDEP) and comorbidities. Key risk factors include genetic mutations, perinatal hypoxia, and metabolic disorders. Many EE patients have a poor prognosis, with lifelong cognitive and motor impairments. Research is urgently needed to identify targeted therapies.

EEs are ideal for mechanistic studies because they often arise from single-gene mutations, enabling precise modeling. Subtypes include Dravet syndrome (SCN1A), Ohtahara syndrome (STXBP1), and CDKL5 deficiency disorder. Public datasets from ClinVar, NCBI Gene, and the Epilepsy Genetics Initiative provide rich mutation data. Open questions include understanding genotype-phenotype correlations, identifying modifier genes, and developing therapies that address the underlying pathophysiology rather than just symptom control.

EEs are primarily caused by dysfunction in ion channels, synaptic proteins, and signaling pathways that regulate neuronal excitability. Key mechanisms include:

1. Ion channel dysfunction: Mutations in voltage-gated sodium (SCN1A, SCN2A), potassium (KCNQ2, KCNQ3), and calcium (CACNA1A) channels alter action potential generation and propagation.

2. Synaptic transmission defects: Mutations in genes encoding synaptic vesicle release machinery (STXBP1, SNAP25) impair neurotransmitter release.

3. GABAergic inhibition disruption: Mutations in GABA receptor subunits (GABRG2, GABRA1) reduce inhibitory signaling, leading to network hyperexcitability.

4. Neuronal development and signaling: Mutations in CDKL5, MEF2C, and other transcription factors disrupt neuronal maturation and synaptic plasticity.

Data from ClinVar, NCBI Gene, and published cohort studies.

EE mutations affect multiple interconnected signaling networks:

• • mTOR pathway: Hyperactivation (e.g., TSC1/2 mutations) leads to abnormal neuronal growth and seizures.
• • MAPK/ERK pathway: Altered in some EE models, affecting synaptic plasticity.
• • Calcium signaling: Mutations in CACNA1A disrupt calcium influx, impacting neurotransmitter release and gene expression.
• • GABAergic signaling: Reduced inhibition shifts network balance toward excitation.
• • Synaptic vesicle cycling: STXBP1 and SNAP25 mutations impair exocytosis, disrupting circuit function.

Organoids offer advantages over 2D cultures by recapitulating neuronal connectivity and network activity, enabling study of seizure-like events.

• • SCN1A knockout mice: Recapitulate Dravet syndrome with spontaneous seizures and premature death.
• • KCNQ2 dominant-negative mice: Model neonatal EE with seizures and developmental delay.
• • STXBP1 heterozygous mice: Show impaired synaptic transmission and cognitive deficits.
• • Zebrafish models: Used for high-throughput drug screening due to optical transparency and genetic tractability.

• • CRISPR/Cas9 technology enables the creation of isogenic cell lines carrying specific EE mutations. For example:
• • SCN1A knockout in SH-SY5Y or iPSC-derived neurons to model loss-of-function.
• • KCNQ2 G279S knock-in to study dominant-negative effects.
• • CDKL5 truncation mutants to investigate kinase activity.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, isogenic controls. These models are essential for target validation, drug screening, and mechanistic studies.

CRISPR knockout and knock-in lines are used to validate the pathogenicity of EE-associated variants. For example, introducing a SCN1A missense mutation into iPSC-derived neurons and measuring sodium current density confirms loss-of-function. Similarly, STXBP1 haploinsufficiency models demonstrate reduced synaptic vesicle release, linking genotype to phenotype.

Isogenic pairs (wild-type vs. mutant) enable high-throughput screening for compounds that rescue the mutant phenotype. For instance, screening for KCNQ2 channel openers in a KCNQ2 mutant cell line can identify potential therapies for neonatal EE. Resistance mechanisms can be studied by exposing cells to existing antiepileptic drugs and monitoring adaptation.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, selectively kill mutant cells. For example, in SCN1A-deficient neurons, targeting compensatory sodium channels may reveal therapeutic vulnerabilities. Transcriptomic and proteomic profiling of isogenic lines can also identify biomarkers for disease progression or drug response.